Istradefylline Versus Opicapone for “Off” Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis

BACKGROUND: In recent times, the US-FDA approved istradefylline and opicapone as an adjunct to levodopa/carbidopa for managing the "off" episodes in Parkinson’s disease. PURPOSE: Current meta-analysis was performed to determine the safety and efficacy of these drugs in the management of “o...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Alok, Gupta, Dhyuti, Dhaneria, Suryaprakash, Sheth, Pranav G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558978/
https://www.ncbi.nlm.nih.gov/pubmed/34733056
http://dx.doi.org/10.1177/09727531211046362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558978/
https://www.ncbi.nlm.nih.gov/pubmed/34733056
http://dx.doi.org/10.1177/09727531211046362

Ejemplares similares